For atopic patients (n = 1102) or patients suffering from psoriasis (n = 833) who came for two consecutive years, a significant SCORAD and PASI improvement was observed on D0 of the second year when compared with D0 of the previous year (P < 0.0001). No significant differences were found between the BD group and RAU group in subjective and objective parameters, except for inflammatory signs. Thirty-four patients with moderate to severe AA (eight men, mean age 40+/-13 years) were enrolled in a randomized, double-blind, right-to-left, placebo-controlled, 24-week trial. During the randomized, investigator-blinded, and vehicle-controlled 12-week maintenance phase, adapalene once daily (QD), or adapalene alternately with its vehicle once daily every other day (QoD), or vehicle QD were applied to the face. Mean symptom scores decreased significantly in the study patients, regardless of their clinical response at the end of the ATP. The infant was treated nightly with methylprednisolone aceponate (MPA) 0.1% (Advantan(®) ) cream, in addition to emollients and an oral antihistamine. Patient-rated indicators for disease severity improved by 39-46% (P < 0.05%). Recently, a new topical formulation (thermophobic foam: Versafoam) of clobetasol propionate 0.05% has been introduced on the market (Olux, Mipharm, Milan, Italy) (CF). The degree of improvement was significantly better on the tacrolimus side (P = 0.005). A decrease in the ulcer healing period was observed in 72.7% of the patients; 75.8% experienced improvement in VAS for pain. Our data should be confirmed by a double-blind study with a larger sample of patients. The aim of this study was to assess the capacity of adapalene gel, 0.1%, to control the number of microcomedones after a combination treatment followed by a maintenance treatment. Both combinations were effective in reducing total lesion (TL), inflammatory lesion (IL) and non-inflammatory lesion (NIL) counts and showed significant global improvement as evaluated by the investigator. We investigated the frequency of HLA ligands for killer cell Immunoglobulin-like receptors (KIRs) in MF patients, evaluating if the presence of particular HLA alleles that are ligands for KIR may have prognostic value. To assess the effectiveness and safety of a 12-week application of mometasone furoate (MMF) 0.1% ointment, with a tapering regimen, in achieving control of VLS signs and symptoms and to detect potential risk factors for VLS non-response. Genetic factors that predispose individuals to Behçet's disease (BD) and periodontal disease. The aim of the present study was to investigate the possible relation of the periodontal scores and single nucleotide polymorphism of TNF-alpha-1031T/C with BD compared with healthy controls (HC) and recurrent aphtous stomatitis (RAS). To develop a model to identify patients at high risk of developing skin cancer who would benefit from regular skin cancer screening. The study includes 46 Caucasian MF patients that, between 1993 and 1997, underwent HLA genomic typing. Good or excellent improvement of colour was found in 63% of patients by PhGA, and in 87% by PGA. Among them, patients were suffering from atopic dermatitis (n = 5916) and psoriasis (n = 4887). Both adapalene and tretinoin produce dramatic reductions in total, inflammatory and non-inflammatory lesion counts, in the range of 69-74% on average. At Baseline, Weeks 2 and 4, investigators assessed clinical severity parameters and collected scalp hair follicles in anagen phase. We excised 38 monitored lesions (seven melanomas in situ, four thin invasive melanomas and 27 melanocytic naevi). Efficacy was assessed by lesion counts, global improvement, quality of life index and measurement of skin barrier functions. July 2020. The recurrence rate of eczema was significantly lower in the group treated with this combination treatment (P < 0.05). Patient parameters improved significantly by day 30 ( P < 0.004) and there was a trend for further improvement at the end of 60 days (for burning, P = 0.046; for pruritus, P = 0.059). A single arm, open study was conducted in three centres. The sequential treatment mometasone furoate 0.1% and salicylic acid 5% followed by mometasone furoate 0.1% proves to be efficient, safe and an excellent option for the following sequence: in-patient and out-patient. Patients were randomized into two groups. Rational healthcare decision-making based on clinical and economic evidence is essential to provide the best possible care for patients with atopic dermatitis (AD). Journal Impact Factor List 2019 – JCR, Web Of Science (PDF, XLS) Journal Impact Factor List 2019. Subgroup analyses did not reveal any statistically significant patient variable that may predict treatment outcome. This may take the form of mass screening, as currently occurs in Germany, or of targeted screening of those at greatest risk. Patients in the IMB group presented LSR that peaked at day 4 and almost completely regressed after 15 days. Mean percentage decrease in clinical severity scores from baseline to last available visit was 63.4% (95% CI 57.7-69) and 54.4% (95% CI 47.9-61) in the ketoconazole- and metronidazole-treated patients, respectively (P = 0.31). A multicentric clinical study was performed to measure the efficiency of mometasone furoate 0.1% and salicylic acid 5% and mometasone furoate 0.1% as sequential local therapy in psoriasis.